Daniel Passeri - Mar 25, 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Mar 25, 2022
Transactions value $
$0
Form type
4
Date filed
3/29/2022, 04:08 PM
Previous filing
Oct 8, 2021
Next filing
Apr 4, 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +100K $0.00 100K Mar 25, 2022 Common Stock 100K $5.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022.